Page last updated: 2024-12-06

ritipenem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ritipenem is a carbapenem antibiotic that exhibits a broad spectrum of antibacterial activity, including against both Gram-positive and Gram-negative bacteria. It is typically administered intravenously and is used to treat various infections, such as pneumonia, urinary tract infections, and skin infections. Ritipenem's synthesis involves complex chemical reactions and is often patented by pharmaceutical companies. It is studied due to its potential effectiveness against antibiotic-resistant strains of bacteria and its unique mechanism of action, which involves inhibiting the formation of bacterial cell walls. The importance of ritipenem lies in its therapeutic value for treating serious infections, particularly those caused by multidrug-resistant bacteria.'

ritipenem: carbapenem antibiotic; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65633
CHEMBL ID70088
SCHEMBL ID155886
MeSH IDM0119432

Synonyms (18)

Synonym
(5r,6s)-6-((1r)-1-hydroxyethyl)-3-(hydroxymethyl)-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-carbamate
ritipenem [inn]
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-(1-hydroxyethyl)-7-oxo-, (5r-(5alpha,6alpha(r*)))-
ritipenem
CHEMBL70088
(5r,6s)-3-(carbamoyloxymethyl)-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
84845-57-8
unii-d4sl77931l
d4sl77931l ,
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-((1r)-1-hydroxyethyl)-7-oxo-, (5r,6s)-
(5r,6s)-3-(((aminocarbonyl)oxy)methyl)-6-((1r)-1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
ritipenem [mi]
4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-(1-hydroxyethyl)-7-oxo-, (5r-(5.alpha.,6.alpha.(r*)))-
SCHEMBL155886
fce22101
DTXSID60868840
Q7336745
gtpl10854

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pertinent pharmacokinetic parameters were determined according to a two-compartment model and correlated among species as an exponential function of body weight, thereby allowing an estimation of pharmacokinetic parameters corresponding to a 70 kg man."( Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic.
Battaglia, R; Efthymiopoulos, C; Strolin Benedetti, M, 1991
)
0.28
" Intravenously administered FCE 22101 at a dose of 250 mg gave peak plasma concentrations of about 12 mg/l and the plasma half-life was about 60 min."( Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
Burman, LA; Cassinelli, G; Corigli, R; Dornbusch, K; Franceschi, G; Norrby, SR; Sassella, D, 1990
)
0.28
" Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%."( Pharmacokinetics of FCE 22101 in man following different modes of administration.
Lewis, DA; Lovering, AM; MacGowan, AP; Pickin, DM; Reeves, DS; Routh, KR; White, LO, 1989
)
0.28
" The proposed method was applied to the pharmacokinetic studies of an active metabolite and open-ring metabolites after oral administration of a penem antibiotic, FCE22891, in dogs."( Simultaneous determination of an active metabolite and open-ring metabolites by high performance liquid chromatography and pharmacokinetic studies of a penem antibiotic, FCE22891, in dogs.
Banno, K; Imado, N; Maki, T; Matsuoka, M; Sato, T, 1998
)
0.3
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" coli and Klebsiella oxytoca were tested for their synergistic and cumulated killing effect (CKE) with the new penems FCE 22101 or FCE 25199 in combination with gentamicin."( Synergy and cumulated killing effect of the penems FCE 22101 and FCE 25199 in combination with gentamicin against bacteria isolated from septicaemia.
Bergholm, AM; Dornbusch, K, 1991
)
0.28
" When combined with gentamicin or netilmicin a bactericidal and synergistic killing was observed within 1-8 h in all strains except Str."( In-vitro activity of the new penems FCE 22101 and FCE 24362 alone or in combination with aminoglycosides against streptococci isolated from patients with endocarditis.
Dornbusch, K; Henning, C; Lindén, E, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
"min/L giving an absolute bioavailability for FCE 22101 of 32%."( Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891.
Lewis, DA; Lovering, AM; MacGowan, AP; Reeves, DS, 1992
)
0.28
" After oral administration in rats of the pivaloyloxymethyl ester prodrug MEN 11505, the relative bioavailability of MEN 10700 was calculated as F=43%."( Synthesis and biological activity of the penem antibiotic MEN 10700 and its orally absorbed ester MEN 11505.
Altamura, M; Arcamone, FM; Crea, A; Maggi, CA; Manzini, S; Perrotta, E; Poma, D; Salimbeni, A; Triolo, A, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
"Rapid, stability-indicating, reversed-phase high-performance liquid chromatographic method for the direct and simultaneous determination of a new beta-lactam molecule and its salt-forming agent in finished dosage forms was studied for the development of injectable formulations."( High-performance liquid chromatographic method for the simultaneous assay of a new synthetic penem molecule and its salt-forming agent in injectable formulations.
Busnelli, V; Farina, M; Finetti, G, 1990
)
0.28
"9% following oral and intravenous dosing respectively."( The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration.
Andrews, JM; Ashby, JP; Wallbridge, D; Webberley, JM; Wise, R, 1988
)
0.27
" It can be seen both in untreated controls and dosed animals."( Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic.
Brughera, M; Dayan, AD; Iatropoulos, MJ; Mazue, G; Newman, AJ; Scampini, G, 1994
)
0.29
"The pharmacokinetics of ritipenem acoxil, the oral prodrug of the antibiotic ritipenem, were studied in volunteers after single and repeated dosing (500 mg, three times daily for 10 days)."( A study of the pharmacokinetics and tolerability of ritipenem acoxil in healthy volunteers following multiple oral dosing.
Carra, L; Frigerio, E; Poggesi, I; Rimoldi, R; Sassella, D; Spinelli, R; Strolin Benedetti, M, 1997
)
0.85
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID70749In Vitro antibacterial activity against (Ec) Escherichia coli ATCC 259221995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID205976In vitro antibacterial activity against Sa(I) Staphylococcus aureus ATCC 292131995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID67231In Vitro antibacterial activity against (Ef) Enterococcus faecalis ATCC 292121995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID164880In Vitro antibacterial activity against (Pa) Pseudomonas aeruginosa ATCC 278531995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID70744In Vitro antibacterial activity against (Ec DC2) hyperpermeable Escherichia coli strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID70746In Vitro antibacterial activity against (Ec SHV) Escherichia coli Beta-lactam producing strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID70748In Vitro antibacterial activity against (Ec TEM2) Escherichia coli Beta-lactam producing strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID205977In vitro antibacterial activity against Sa(II) Staphylococcus aureus ATCC 259231995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID164881In Vitro antibacterial activity against (Pa) hyperpermeable Pseudomonas aeruginosa Beta-lactam lacking strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID164879In Vitro antibacterial activity against (Pa G242) hyperpermeable Pseudomonas aeruginosa strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID70747In Vitro antibacterial activity against (Ec TEM1) Escherichia coli Beta-lactam producing strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID205974In vitro antibacterial activity against Sa MR(I) heterogeneous methicillin resistant Staphylococcus aureus1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID70745In Vitro antibacterial activity against (Ec L) Escherichia coli Beta-lactam lacking strain1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID205975In vitro antibacterial activity against Sa MR(II) homogeneous methicillin resistant Staphylococcus aureus1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (60.29)18.7374
1990's24 (35.29)18.2507
2000's3 (4.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.34 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (10.14%)5.53%
Reviews2 (2.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (86.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]